Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Huanglian Wendan Decoction in Metabolic Syndrome
NCT07702669Completed
- Sponsor
- The First Affiliated Hospital of Heilongjiang University of Chinese Medicine
- Start
- Oct 2023
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
Randomised, open-label trial of Modified Huanglian Wendan Decoction in metabolic syndrome (2 arms), sponsored by The First Affiliated Hospital of Heilongjiang University of Chinese Medicine. Primary endpoints: Malondialdehyde at 3 months, Superoxide Dismutase at 3 months and 4 more. Started Oct 2023; status: completed.
02
Drugs
Modified Huanglian Wendan Decoction
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT07702669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07702669.